Y-mAbs Therapeutics announces new business units for Radiopharmaceuticals and DANYELZA, reporting preliminary revenues of $88 million for 2024. Y-mAbs Therapeutics, Inc. has announced strategic ...

A platform approach to bioprocessing uses the same set of protocols and systems found during early phase development. Scientists then transfer the protocols, by either scaling-up or scaling-out, ...

Nicole Germino, an analyst from Truist Financial, has initiated a new Buy rating on Y-Mabs Therapeutics (YMAB). Nicole Germino’s rating is based on the potential of Y-Mabs Therapeutics’ diversified ...

New business model reflects strategic transition to a global biotech platform focused on business development and translational clinical development to accelerate access to innovative medicines for ...

NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and ...

This suite automates the commissioning, qualification, and validation (CQV) of processes, equipment, and systems. It includes three AI-enabled applications: Together, these systems work in tandem to ...

See how BioDlink’s digital-intelligence platform is driving three major improvements in lyophilization workflows.

- First Preclinical Data Sets Demonstrating Potential to Re-Dose with AAVHSCs and to Identify Genomic Sites with Improved Gene Editing Integration Efficiency - “These new data to be presented during ...

Downstream bioprocessing steps have long been a challenge to drug manufacturers, particularly the chromatography step for purification of monoclonal antibodies (mAbs). The complexity of traditional ...